BiotechTube

DCCR + Placebo for DCCR

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

May 9, 2018 → May 1, 2020

NCT ID
NCT03440814

About DCCR + Placebo for DCCR

DCCR + Placebo for DCCR is a phase 3 stage product being developed by Soleno Therapeutics for Prader-Willi Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03440814. Target conditions include Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03440814Phase 3Completed

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Octreotide + PlaceboNovartisPre-clinical
23
Norditropin SimpleXxNovo NordiskPre-clinical
22
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
76
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 2
49
SetmelanotideRhythm PharmaceuticalsPhase 2
49
RGH-706 + PlaceboRichter GedeonPhase 2
49
CarbetocinAcadia PharmaceuticalsPhase 3
72
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
DCCRSoleno TherapeuticsPhase 3
72
DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
PitolisantHarmony BiosciencesPhase 3
72
Pitolisant tabletHarmony BiosciencesPhase 3
72
Pitolisant oral tablets + Placebo oral tabletHarmony BiosciencesPhase 2
47
DCCRSoleno TherapeuticsPhase 3
72
VYKAT XRSoleno TherapeuticsPre-clinical
18
NNZ-2591Neuren PharmaceuticalsPhase 2
47
BMB-101 + PlaceboBright Minds BiosciencesPhase 2
47
ARD-101Aardvark TherapeuticsPhase 2
44

Other Products from Soleno Therapeutics

DCCRPhase 3
72
DCCR + DCCR + Placebo for DCCRPhase 3
72
DCCRPhase 3
72
DCCR (diazoxide choline) extended-release tabletsPhase 2
47
VYKAT XRPre-clinical
18